Operative intervention for recurrent adrenocortical cancer

Benzon M. Dy, Kevin B. Wise, Melanie L. Richards, William Francis Young, Clive S. Grant, Keith C. Bible, Jordan Rosedahl, William S. Harmsen, David R. Farley, Geoffrey B. Thompson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Introduction Adrenocortical cancer (ACC) recurs despite apparent complete resection. We examined the survival and palliative benefit of resection for recurrent ACC. Methods A review of all patients undergoing operation for ACC between 1980 and 2010 at our institution was performed in which we compared resection with nonoperative therapy. Results Overall, 164 patients underwent operation for ACC, 125 of whom underwent a complete resection (R0). Recurrence occurred in 93 R0 patients (median, 15 months; range, 1.5-150 months). Symptoms at recurrence were present in 71% (66/93), including pain (34%) and hormone excess (43%). There were 67 patients who underwent reoperation for recurrence. Forty-eight of 67 patients underwent R0 resection for recurrence. Operative patients had a greater overall operative versus nonoperative management or no therapy (65 months vs 6 months, P <.01). Median survival for nonoperatively managed patients (226 days) and those undergoing no therapy (179 days) was less than for debulking (1,272 days, P =.002). R0 for recurrence (P =.005) and a disease-free interval >6 months (P <.001) were associated with survival after operation, whereas original tumor size (P =.47), grade (P =.8), and stage (P =.23) were not. Pain and hormonal symptoms improved in 84% of operative patients versus 29% of nonoperatively managed patients (P =.005). Debulking had similar symptomatic improvement to R0 resection (P =.52). Conclusion Patients with recurrent ACC can benefit from operative intervention with improvement in survival and symptoms. Patients with a disease-free interval >6 months and complete resection are likely to benefit from resection of the recurrence, but the near universal improvement in symptoms may expand the criteria for operation in recurrent ACC.

Original languageEnglish (US)
Pages (from-to)1292-1299
Number of pages8
JournalSurgery (United States)
Volume154
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Adrenal Cortex Neoplasms
Recurrence
Reoperation
Hormones
Pain
Survival
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Dy, B. M., Wise, K. B., Richards, M. L., Young, W. F., Grant, C. S., Bible, K. C., ... Thompson, G. B. (2013). Operative intervention for recurrent adrenocortical cancer. Surgery (United States), 154(6), 1292-1299. https://doi.org/10.1016/j.surg.2013.06.033

Operative intervention for recurrent adrenocortical cancer. / Dy, Benzon M.; Wise, Kevin B.; Richards, Melanie L.; Young, William Francis; Grant, Clive S.; Bible, Keith C.; Rosedahl, Jordan; Harmsen, William S.; Farley, David R.; Thompson, Geoffrey B.

In: Surgery (United States), Vol. 154, No. 6, 12.2013, p. 1292-1299.

Research output: Contribution to journalArticle

Dy, BM, Wise, KB, Richards, ML, Young, WF, Grant, CS, Bible, KC, Rosedahl, J, Harmsen, WS, Farley, DR & Thompson, GB 2013, 'Operative intervention for recurrent adrenocortical cancer', Surgery (United States), vol. 154, no. 6, pp. 1292-1299. https://doi.org/10.1016/j.surg.2013.06.033
Dy, Benzon M. ; Wise, Kevin B. ; Richards, Melanie L. ; Young, William Francis ; Grant, Clive S. ; Bible, Keith C. ; Rosedahl, Jordan ; Harmsen, William S. ; Farley, David R. ; Thompson, Geoffrey B. / Operative intervention for recurrent adrenocortical cancer. In: Surgery (United States). 2013 ; Vol. 154, No. 6. pp. 1292-1299.
@article{5b940d4645664a6988bf98a7ec92183a,
title = "Operative intervention for recurrent adrenocortical cancer",
abstract = "Introduction Adrenocortical cancer (ACC) recurs despite apparent complete resection. We examined the survival and palliative benefit of resection for recurrent ACC. Methods A review of all patients undergoing operation for ACC between 1980 and 2010 at our institution was performed in which we compared resection with nonoperative therapy. Results Overall, 164 patients underwent operation for ACC, 125 of whom underwent a complete resection (R0). Recurrence occurred in 93 R0 patients (median, 15 months; range, 1.5-150 months). Symptoms at recurrence were present in 71{\%} (66/93), including pain (34{\%}) and hormone excess (43{\%}). There were 67 patients who underwent reoperation for recurrence. Forty-eight of 67 patients underwent R0 resection for recurrence. Operative patients had a greater overall operative versus nonoperative management or no therapy (65 months vs 6 months, P <.01). Median survival for nonoperatively managed patients (226 days) and those undergoing no therapy (179 days) was less than for debulking (1,272 days, P =.002). R0 for recurrence (P =.005) and a disease-free interval >6 months (P <.001) were associated with survival after operation, whereas original tumor size (P =.47), grade (P =.8), and stage (P =.23) were not. Pain and hormonal symptoms improved in 84{\%} of operative patients versus 29{\%} of nonoperatively managed patients (P =.005). Debulking had similar symptomatic improvement to R0 resection (P =.52). Conclusion Patients with recurrent ACC can benefit from operative intervention with improvement in survival and symptoms. Patients with a disease-free interval >6 months and complete resection are likely to benefit from resection of the recurrence, but the near universal improvement in symptoms may expand the criteria for operation in recurrent ACC.",
author = "Dy, {Benzon M.} and Wise, {Kevin B.} and Richards, {Melanie L.} and Young, {William Francis} and Grant, {Clive S.} and Bible, {Keith C.} and Jordan Rosedahl and Harmsen, {William S.} and Farley, {David R.} and Thompson, {Geoffrey B.}",
year = "2013",
month = "12",
doi = "10.1016/j.surg.2013.06.033",
language = "English (US)",
volume = "154",
pages = "1292--1299",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Operative intervention for recurrent adrenocortical cancer

AU - Dy, Benzon M.

AU - Wise, Kevin B.

AU - Richards, Melanie L.

AU - Young, William Francis

AU - Grant, Clive S.

AU - Bible, Keith C.

AU - Rosedahl, Jordan

AU - Harmsen, William S.

AU - Farley, David R.

AU - Thompson, Geoffrey B.

PY - 2013/12

Y1 - 2013/12

N2 - Introduction Adrenocortical cancer (ACC) recurs despite apparent complete resection. We examined the survival and palliative benefit of resection for recurrent ACC. Methods A review of all patients undergoing operation for ACC between 1980 and 2010 at our institution was performed in which we compared resection with nonoperative therapy. Results Overall, 164 patients underwent operation for ACC, 125 of whom underwent a complete resection (R0). Recurrence occurred in 93 R0 patients (median, 15 months; range, 1.5-150 months). Symptoms at recurrence were present in 71% (66/93), including pain (34%) and hormone excess (43%). There were 67 patients who underwent reoperation for recurrence. Forty-eight of 67 patients underwent R0 resection for recurrence. Operative patients had a greater overall operative versus nonoperative management or no therapy (65 months vs 6 months, P <.01). Median survival for nonoperatively managed patients (226 days) and those undergoing no therapy (179 days) was less than for debulking (1,272 days, P =.002). R0 for recurrence (P =.005) and a disease-free interval >6 months (P <.001) were associated with survival after operation, whereas original tumor size (P =.47), grade (P =.8), and stage (P =.23) were not. Pain and hormonal symptoms improved in 84% of operative patients versus 29% of nonoperatively managed patients (P =.005). Debulking had similar symptomatic improvement to R0 resection (P =.52). Conclusion Patients with recurrent ACC can benefit from operative intervention with improvement in survival and symptoms. Patients with a disease-free interval >6 months and complete resection are likely to benefit from resection of the recurrence, but the near universal improvement in symptoms may expand the criteria for operation in recurrent ACC.

AB - Introduction Adrenocortical cancer (ACC) recurs despite apparent complete resection. We examined the survival and palliative benefit of resection for recurrent ACC. Methods A review of all patients undergoing operation for ACC between 1980 and 2010 at our institution was performed in which we compared resection with nonoperative therapy. Results Overall, 164 patients underwent operation for ACC, 125 of whom underwent a complete resection (R0). Recurrence occurred in 93 R0 patients (median, 15 months; range, 1.5-150 months). Symptoms at recurrence were present in 71% (66/93), including pain (34%) and hormone excess (43%). There were 67 patients who underwent reoperation for recurrence. Forty-eight of 67 patients underwent R0 resection for recurrence. Operative patients had a greater overall operative versus nonoperative management or no therapy (65 months vs 6 months, P <.01). Median survival for nonoperatively managed patients (226 days) and those undergoing no therapy (179 days) was less than for debulking (1,272 days, P =.002). R0 for recurrence (P =.005) and a disease-free interval >6 months (P <.001) were associated with survival after operation, whereas original tumor size (P =.47), grade (P =.8), and stage (P =.23) were not. Pain and hormonal symptoms improved in 84% of operative patients versus 29% of nonoperatively managed patients (P =.005). Debulking had similar symptomatic improvement to R0 resection (P =.52). Conclusion Patients with recurrent ACC can benefit from operative intervention with improvement in survival and symptoms. Patients with a disease-free interval >6 months and complete resection are likely to benefit from resection of the recurrence, but the near universal improvement in symptoms may expand the criteria for operation in recurrent ACC.

UR - http://www.scopus.com/inward/record.url?scp=84887925979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887925979&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2013.06.033

DO - 10.1016/j.surg.2013.06.033

M3 - Article

VL - 154

SP - 1292

EP - 1299

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -